Actos Cancer Risk Results in French Recall for Diabetes Drug

French health authorities have suspended Actos sales, following data that provides further evidence that users of the diabetes drug may face an increased risk of bladder cancer. 

The Actos recall was announced on Thursday by AFSSAPS, the medical regulatory agency of France.

French authorities also pulled a drug known as Competact, a combination of Actos and metaformin, from the market as well. Both are manufactured by Takeda Pharmaceuticals.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The French decision to remove Actos from the market came after a review of French public insurance data found a slight increase in the risk of bladder cancer from Actos. In France, the drug is taken by about 230,000 people.

AFSSAPS said that patients should not stop taking the drug without consulting their physician, but told doctors they should no longer prescribe it.

An Actos cancer risk has been suggested in a number of recent studies.

In September 2010, the FDA announced that it was investigating the potential link between bladder cancer and Actos after data from an ongoing 10-year study by Takeda Pharmaceitucals suggested that users may have an increased risk of cancer from Actos the longer they took the medication. However, to date, the FDA has not concluded that there is an increased risk of cancer from Actos.

Last month, a study by Italian researchers found a disproportionate number of Actos bladder cancer reports in the FDA’s own Adverse Event Reporting System Records. However, that study did not establish a causal effect between Actos and bladder cancer.

Actos (pioglitazone) was approved by FDA to treat Type 2 Diabetes in July, 1999. It is Takeda Pharmaceuticals’ best-selling drug, with sales of $3.4 billion last year.

Sales have increased in recent years after a number of studies have suggested that Actos may be safer than its competitor, Avandia, which has been linked to an increased risk of heart attacks and deaths.

A number of former users who have been diagnosed with bladder cancer have contacted lawyers in recent months to determine whether they may be entitled to compensation through an Actos lawsuit as a result of the manufacturers failure to adequately warn about the potential side effects.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted yesterday)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted yesterday)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.

Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant
Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant (Posted 2 days ago)

Following a $60 million verdict in a similar lawsuit earlier this year, trial is underway involving claims brought by an Illinois mother, whose premature daughter developed NEC from Similac, alleging that Abbott failed to warn parents and medical staff of the devastating risks associated with the cow's milk-based formula.